PharmaCyte Biotech, Inc. - 10-Q filing on 2012-03-21

Receivables, Loans, Notes Receivable, and Others	9 Months Ended
Jan. 31, 2012
Receivables [Abstract]
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	NOTE 4 – ACCOUNTS RECEIVABLE The Company recognizes receivables predominately on sales of its Cinnergen product. At January 31, 2012 and April 30, 2011 the company recorded an allowance for doubtful accounts of $0 and $3,906, respectively.

Receivables, Loans, Notes Receivable, and Others

9 Months Ended

Jan. 31, 2012

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

NOTE 4 – ACCOUNTS RECEIVABLE

The Company recognizes receivables predominately on sales of its Cinnergen product. At January 31, 2012 and April 30, 2011 the company recorded an allowance for doubtful accounts of $0 and $3,906, respectively.